Topic: protein chemistry

Kymera Therapeutics

Looking to harness the body’s protein degradation processes, Kymera has raised more than $150 million for its pipeline of small molecules, led by a program targeting IRAK4, a protein involved in disease-signaling pathways.

Frontier Medicines

By using chemoproteomic techniques to screen large numbers of targets within an active cellular environment, and combining them with a protein database containing over 100,000 novel hot spots, Frontier hopes to develop at least three internal clinical programs, starting with cancer.

Tools to Meet the Challenge of Complex Protein Expression

Join us to learn how recent enhancements to protein expression platforms can significantly increase expression levels for complex proteins. New technologies for simplifying and increasing expression levels of multi-chain and complex proteins will be presented.